All In Biotech

Drug Trial Radar · NCT06805812

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Predictive Impact of Peripheral Blood Lymphocytes on clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Last checked: Nov 19, 2026Latest source record: Feb 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

3,500

Planned (sponsor's estimate)

Start

May 1, 2023

Primary completion

Dec 31, 2030

Study completion Dec 31, 2040

Sponsor

Lead sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
European Institute of Oncology, Italy; Humanitas Research Hospital IRCCS, Rozzano-Milan; Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia; OSPEDALE ASST CREMONA; IOV Oncologico Veneto Padova; ASST Fatebenefratelli Sacco; IRCCS Fondazione Salvatore Maugeri, Pavia, Italy; IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori Meldola; Azienda Ospedaliero-Universitaria di Modena; Azienda Ospedaliero Universitaria Maggiore della Carita; A.O.U. Federico II, Napoli; San Raffaele University Hospital, Italy; Centro di Riferimento Oncologico - Aviano; Azienda Socio-Sanitaria Territoriale Lariana; Azienda ULSS 3 Serenissima, Ospedale di Mirano; Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma; Fondazione IRCCS Policlinico San Matteo di Pavia; IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; Fondazione Policlinico Universitario Agostino Gemelli IRCCS; Azienda Ospedaliero-Universitaria Careggi; Humanitas, Istituto Clinico Catanese; Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale; Fondazione Policlinico Universitario Campus Bio-Medico; Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
First posted
Feb 3, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PALMARES-2 is a retrospective/prospective, observational, multicenter, population-based study, aiming at providing real-world evidences on HR+/HER2- aBC patients treated with first-line CDK4/6i plus ET. The present study has the objective to collect data coming from different sources, i.e. RWD, medical images and biological samples, from patients treated with CDK4/6i as first-line of therapy for HR+/HER2- aBC. In consideration of the complexity of data collected and different objectives of the study, this master protocol foresees different sub-studies, which encompasses different methodologies for data collection, data extraction and analyses.

Conditions

  • Breast Adenocarcinoma
  • Breast Cancer Stage IV
  • Breast Cancer, Metastatic
  • Breast Carcinoma
  • Breast Diseases
  • Breast Neoplasms
  • Breast Neoplasms, Male
  • Breast Cancer
  • Breast Cancer With Metastatic Bone Disease
  • Breast Cancers
  • Breast Neoplasm
  • Breast Tumors
  • HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer
  • HR+ Advanced or Metastatic Breast Cancer
  • HR+/HER2- Breast Cancer
  • HRpos Breast Neoplasms
  • HR-positive, HER2-negative Advanced Breast Cancer
  • HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
  • HR-positive Breast Cancer
  • Hormone Receptor-Positive Breast Cancer
  • Hormone Receptor Positive Breast Adenocarcinoma
  • Hormone Receptor Positive Breast Carcinoma
  • Hormone Receptor Positive Breast Neoplasms
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
  • Hormone Receptor Positive Malignant Neoplasm of Breast
  • Hormone Receptor Positive Metastatic Breast Cancer
  • Hormone Receptor Positive, HER2 Negative Breast Cancer
  • Hormone Receptor Negative Breast Cancer
  • Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
  • Hormone Receptor Positive Breast Cancer
  • Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer
  • Hormone Receptor Positive, HER2-negative Neoplasms
  • Hormone Receptor Positive, HER2-low Neoplasms
  • Hormone Receptor Positive (HR+), HER2-negative Breast Cancer
  • Hormone Receptor (HR)-Positive Breast Cancer
  • Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
  • Palbociclib
  • Ribociclib
  • Abemaciclib
  • CDK4/6 Inhibitor
  • CDK4/6 Inhibitors

Interventions

  • PalbociclibDrug

    Administered in combination with endocrine therapy

  • RibociclibDrug

    Administered in combination with endocrine therapy

  • AbemaciclibDrug

    Administered in combination with endocrine therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From the first-line treatment start to date of any-cause death or last follow up, up to 120 months

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Centro di Riferimento Oncologico IRCCS

    Aviano, Italy · Recruiting

  • Azienda Socio Sanitaria Territoriale degli Spedali Civili

    Brescia, Italy · Recruiting

  • Humanitas Istituto Clinico Catanese

    Catania, Italy · Recruiting

  • ASST Lariana - Ospedale Sant'Anna

    Como, Italy · Recruiting

  • ASST Ospedale Maggiore

    Cremona, Italy · Recruiting

  • Azienda Ospedaliero Universitaria Careggi

    Florence, Italy · Recruiting

  • Ospedale San Martino

    Genova, Italy · Recruiting

  • Istituto Tumori della Romagna IRST IRCCS

    Meldola, Italy · Recruiting

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore

    Milan, Italy · Recruiting

  • IEO Istituto Europeo di Oncologia

    Milan, Italy · Recruiting

  • IRCCS Ospedale San Raffaele

    Milan, Italy · Recruiting

  • Ospedale ASST Fatebenefratelli Sacco

    Milan, Italy · Recruiting

  • ULSS 3 Veneto

    Mirano, Italy · Recruiting

  • Azienda Ospedaliero-Universitaria

    Modena, Italy · Recruiting

  • Azienda Ospedaliero-Universitaria Federico II

    Naples, Italy · Recruiting

  • Istituto Nazionale Tumori IRCCS Fondazione G. Pascale

    Naples, Italy · Recruiting

  • Ospedale Maggiore della Carità

    Novara, Italy · Recruiting

  • IOV Istituto Oncologico Veneto IRCCS

    Padova, Italy · Recruiting

  • Fondazione IRCCS Policlinico San Matteo

    Pavia, Italy · Recruiting

  • IRCCS - ICS Maugeri

    Pavia, Italy · Recruiting

  • Clinica Ospedaliero - Universitaria Policlinico Umberto I

    Roma, Italy · Recruiting

  • Policlinico Universitario Campus Bio-Medico

    Roma, Italy · Recruiting

  • Policlinico Universitario Fondazione Agostino Gemelli

    Roma, Italy · Recruiting

  • Istituto Clinico Humanitas

    Rozzano, Italy · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.